476.95
price up icon1.45%   6.82
after-market Dopo l'orario di chiusura: 475.58 -1.37 -0.29%
loading

Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie

pulisher
01:18 AM

Vertex Pharmaceuticals (VRTX) Advances Cystic Fibrosis Treatment With ALYFTREK Approval in Canada - Yahoo Finance

01:18 AM
pulisher
06:37 AM

Vertex Pharmaceuticals Incorporated Stock Analysis and ForecastHigh-yield trading alerts - Autocar Professional

06:37 AM
pulisher
Jul 22, 2025

Vertex Pharmaceuticals (VRTX) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance

Jul 22, 2025
pulisher
Jul 22, 2025

Cystic Fibrosis Pipeline Outlook 2025: Insights into Drug Development and Leading 50+ Companies - The Globe and Mail

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Vertex Pharmaceuticals Incorporated stockFree Stock Chart Pattern Guide - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals: Pioneering Orphan Drug Innovation in Cystic Fibrosis and Cementing Market Leadership - AInvest

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Announces Marketing Authorization in Canada for ALYFTREK, a Once-Daily Next-Generation CFTR Modulator for the Treatment of Cystic Fibrosis - The Malaysian Reserve

Jul 22, 2025
pulisher
Jul 22, 2025

Is Vertex Pharmaceuticals Incorporated a good long term investmentTriple-digit wealth increases - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Vertex Pharmaceuticals' Quarterly Earnings Preview: What You Need To Know - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

What drives Vertex Pharmaceuticals Incorporated stock priceConsistent triple returns - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

3 Healthcare Stocks to Buy Before They Announce Game-Changing Clinical Trial Results - The Motley Fool

Jul 22, 2025
pulisher
Jul 21, 2025

Sickle Cell Disease Market Set to Grow Substantially Through 2034, DelveInsight Projects | Sanofi, CSL Behring, ITB-Med LLC, Novo Nordisk A/S, Fortrea, Inc., Novartis, Afimmune, Pfizer, ADDMEDICA SASA - The Globe and Mail

Jul 21, 2025
pulisher
Jul 21, 2025

Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace

Jul 21, 2025
pulisher
Jul 18, 2025

Here's How Much $1000 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today - Benzinga

Jul 18, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals (VRTX): Can Strong Catalysts Propel Outperformance Ahead of Earnings? - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Lobbying Update: $1,140,000 of VERTEX PHARMACEUTICALS INCORPORATED lobbying was just disclosed - Nasdaq

Jul 16, 2025
pulisher
Jul 16, 2025

Diabetic Neuropathic Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Helixmith, Vertex Pharma, Eisai, NeuroBo Pharma, AstraZeneca, Eli Lilly and Company - Barchart.com

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance

Jul 16, 2025
pulisher
Jul 16, 2025

Vertex Pharmaceuticals: Strong Growth Driven by Cystic Fibrosis Success and Strategic Expansions - TipRanks

Jul 16, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals Surges to 213th in Trading Volume with $460 Million in Shares Traded Despite Stock Price Decline - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Secures NHS England Agreement For Next-In-Class Cystic Fibrosis Treatment - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

England Leads Europe In Reimbursing Vertex’s Next-In-Class CF Drug Alyftrek - insights.citeline.com

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures Alyftrek coverage in England; Merck starts Phase 3 trials of HIV drug - BioPharma Dive

Jul 15, 2025
pulisher
Jul 15, 2025

Peripheral Neuropathic Pain Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Trevena, Afasci, Lexicon Pharma, Haisco Pharma, Vertex Pharma - Barchart.com

Jul 15, 2025
pulisher
Jul 15, 2025

EU Commission Approves Vertex Pharmaceutical’s (VRTX) Cystic Fibrosis Treatment - Insider Monkey

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex secures NHS deal for once-daily cystic fibrosis therapy - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals And 2 Other Stocks That May Be Trading Below Their Estimated Value - Yahoo Finance

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex’s triple combination cystic fibrosis therapy Alyftrek recommended by NICE - PMLiVE

Jul 15, 2025
pulisher
Jul 15, 2025

NICE backs Vertex's cystic fibrosis triple combo Alyftrek - FirstWord Pharma

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Pharmaceuticals (VRTX) Receives a Buy from J.P. Morgan - The Globe and Mail

Jul 15, 2025
pulisher
Jul 15, 2025

New cystic fibrosis triple from Vertex backed for NHS use - pharmaphorum

Jul 15, 2025
pulisher
Jul 15, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX™, a First-in-Class Non-Opioid Treatment for Adults With Moderate-to-Severe Acute Pain - BioSpace

Jul 15, 2025
pulisher
Jul 14, 2025

Vertex Pharmaceuticals' ALYFTREK® Approval: A Catalyst for EU Dominance and Revenue Growth? - AInvest

Jul 14, 2025
pulisher
Jul 14, 2025

(Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire

Jul 14, 2025
pulisher
Jul 14, 2025

Vertex Named a Premier, Inc. Breakthroughs Innovation Celebration Winner for JOURNAVX - Business Wire

Jul 14, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals: A Steady Hand in a Volatile Market - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Vertex Pharmaceuticals Leads Biotech Stocks with 16%+ YTD Increase - AInvest

Jul 13, 2025
pulisher
Jul 13, 2025

Why Vertex Pharmaceuticals Continues To Outperfrom (NASDAQ:VRTX) - Seeking Alpha

Jul 13, 2025
pulisher
Jul 11, 2025

Small Fiber Neuropathy Market Growth Projections 2023-2032: DelveInsight Analysis | Grünenthal, Averitas Pharma, Daiichi Sankyo, Vertex Pharma, Helixmith, Lexicon Pharma, Glenmark Pharma, Regency - Barchart.com

Jul 11, 2025
pulisher
Jul 10, 2025

Regulatory tracker: Vertex, NHS England reach reimbursement deal for CF drug Alyftrek - Fierce Pharma

Jul 10, 2025
pulisher
Jul 09, 2025

Vertex: Latest Casgevy Data Highlights Efficacy Amid Slow Commercial Launch (NASDAQ:VRTX) - Seeking Alpha

Jul 09, 2025
pulisher
Jul 09, 2025

Vertex Pharmaceuticals’ cystic fibrosis therapy Alyftrek granted EC approval - PMLiVE

Jul 09, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals Q2 2025 Earnings: A Catalyst for Dominance in Rare Disease Therapeutics - AInvest

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex to Announce Second Quarter 2025 Financial Results on August 4th - Business Wire

Jul 08, 2025
pulisher
Jul 08, 2025

Cystic Fibrosis Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma - Barchart.com

Jul 08, 2025
pulisher
Jul 08, 2025

RBC Capital Remains a Hold on Vertex Pharmaceuticals (VRTX) - The Globe and Mail

Jul 08, 2025
pulisher
Jul 08, 2025

Do You Believe in the Upside Potential of Vertex Pharmaceuticals (VRTX)? - Insider Monkey

Jul 08, 2025
pulisher
Jul 08, 2025

FDA Approves Suzetrigine by Vertex Pharmaceuticals for Acute Pain Relief in Adults - geneonline.com

Jul 08, 2025
pulisher
Jul 08, 2025

Vertex Pharmaceuticals to Announce Q2 2025 Earnings on August 4th - AInvest

Jul 08, 2025
$572.39
price up icon 2.04%
$325.64
price up icon 0.11%
$575.42
price up icon 0.73%
biotechnology ONC
$294.83
price down icon 0.26%
$114.60
price up icon 2.84%
Capitalizzazione:     |  Volume (24 ore):